Citi Reiterates Neutral Rating on Alnylam Pharmaceuticals (ALNY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Strong AI earnings lift S&P 500, Nasdaq as inflation data calms rate-hike jitters
- Oil prices little changed as investors weigh lower demand against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Alnylam Pharmaceuticals (ALNY) PT Raised to $307 at BofA Securities
September 4, 2024 5:22 AM EDTBofA Securities analyst Tazeen Ahmad raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $307.00 (from $295.00) while maintaining a Buy rating.
The analyst comments "ALNY hosted an analyst reception after the detailed HELIOS-B data at ESC (see Aug 30 note). The main... More
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
September 3, 2024 8:05 AM EDTStifel analyst Paul Matteis reiterated a Buy rating and $295.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
The analyst comments "With a few days to reflect, full HELIOS-B data were slightly less compelling than we expected, simply because we thought the results might offer... More
Wolfe Research Reiterates Peerperform Rating on Alnylam Pharmaceuticals (ALNY)
September 3, 2024 7:29 AM EDTWolfe Research analyst Andy Chen reiterated a Peerperform rating on Alnylam Pharmaceuticals (NASDAQ: ALNY).
The analyst comments "ALNY Setup & Shifting Debate. On Aug 30 ESC news, ALNY (PP) traded -8%, IONS (OP) -4% whereas BBIO +13% (not covered). We expect ALNY to have little volatility until... More
Barclays Reiterates Overweight Rating on Alnylam Pharmaceuticals (ALNY)
September 3, 2024 5:25 AM EDTBarclays analyst Gena Wang reiterated an Overweight rating and $295.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
The analyst comments "Key takeaways. At ESC 2024, ALNY presented detailed data from Ph3 HELIOS-B, showing all- cause-mortality (ACM) reduction was stat sig at 33-36 mon (HR 0.694, p=0.0389), with... More
Alnylam Pharma (ALNY) Management Said There Was a Typo Error on Discussant Slide - Stat
August 30, 2024 8:50 AM EDTAlnylam Pharma (NASDAQ: ALNY) Management Said There Was a Typo Error on Discussant Slide - Stat
On $ALNY call, management said there was a typo error on this discussant slide. At 30 months, ACM RRR was 31%, not 13% pic.twitter.com/pLRJaNmkB5
Adam Feuerstein (@adamfeuerstein) August 30, 2024... More
BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY) following HELIOS-B readout
August 30, 2024 8:21 AM EDTBMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $300.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
The analyst commented: "HELIOS-B data demonstrate: (1) Separation between Amvuttra/placebo ACM curves by ~19mo, similar to stabilizers; (2) Strong Amvuttra effect on top of Tafamidis,... More
Stifel Reiterates Alnylam Pharmaceuticals (ALNY) at Buy following HELIOS-B readout, 'full HELIOS-B data look strong'
August 30, 2024 7:57 AM EDT(Updated - August 30, 2024 7:58 AM EDT)
Stifel analyst Paul Matteis reiterated a Buy rating and $295.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
The analyst commented: "Overall we think full HELIOS-B data look strong, de-risking approval and a blockbuster opportunity, while also... More
Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises
August 30, 2024 7:39 AM EDTAlnylam Pharma (NASDAQ: ALNY) shares tumbled 11.5% Friday following the release of results from its HELIOS-B Phase 3 study of vutrisiran, despite the study meeting all primary and secondary endpoints.
The investigational RNAi therapeutic, aimed at treating ATTR amyloidosis with cardiomyopathy (ATTR-CM), was shown to reduce the risk of death and cardiovascular events by 28% compared to placebo in the overall... More
Alnylam Pharma (ALNY) Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran
August 30, 2024 6:11 AM EDTAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).
The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Results from the HELIOS-B study were also simultaneously... More
